Interlaboratory Comparison of Antibody-Free LC-MS/MS Measurements of C-peptide and Insulin
Authors:
Open Access
- 29 March 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 70 (6) , 855-864
Abstract
The enhanced precision and selectivity of liquid chromatography–tandem mass spectrometry (LC-MS/MS) makes it an attractive alternative to certain clinical immunoassays. Easily transferrable work flows could help facilitate harmonization and ensure high-quality patient care. We aimed to evaluate the interlaboratory comparability of antibody-free multiplexed insulin and C-peptide LC-MS/MS measurements. The laboratories that comprise the Targeted Mass Spectrometry Assays for Diabetes and Obesity Research (TaMADOR) consortium verified the performance of a validated peptide-based assay (reproducibility, linearity, and lower limit of the measuring interval [LLMI]). An interlaboratory comparison study was then performed using shared calibrators, de-identified leftover laboratory samples, and reference materials. During verification, the measurements were precise (2.7% to 3.7%CV), linear (4 to 15 ng/mL for C-peptide and 2 to 14 ng/mL for insulin), and sensitive (LLMI of 0.04 to 0.10 ng/mL for C-peptide and 0.03 ng/mL for insulin). Median imprecision across the 3 laboratories was 13.4% (inter-quartile range [IQR] 11.6%) for C-peptide and 22.2% (IQR 20.9%) for insulin using individual measurements, and 10.8% (IQR 8.7%) and 15.3% (IQR 14.9%) for C-peptide and insulin, respectively, when replicate measurements were averaged. Method comparison with the University of Missouri reference method for C-peptide demonstrated a robust linear correlation with a slope of 1.044 and r2 = 0.99. Our results suggest that combined LC-MS/MS measurements of C-peptide and insulin are robust and adaptable and that standardization with a reference measurement procedure could allow accurate and precise measurements across sites, which could be important to diabetes research and help patient care in the future.Keywords
This publication has 27 references indexed in Scilit:
- Automated LC-MS/MS: Ready for the clinical routine Laboratory?Journal of Mass Spectrometry and Advances in the Clinical Lab, 2023
- Pitfalls in Diagnosing Hypoglycemia Due to Exogenous InsulinMayo Clinic Proceedings, 2022
- A distributable LC-MS/MS method for the measurement of serum thyroglobulinJournal of Mass Spectrometry and Advances in the Clinical Lab, 2022
- Multiplexed quantification of insulin and C-peptide by LC-MS/MS without the use of antibodiesJournal of Mass Spectrometry and Advances in the Clinical Lab, 2022
- Development and validation of a novel LC-MS/MS assay for C-peptide in human serumJournal of Mass Spectrometry and Advances in the Clinical Lab, 2020
- Calibration Using a Single-Point External Reference Material Harmonizes Quantitative Mass Spectrometry Proteomics Data between Platforms and LaboratoriesAnalytical Chemistry, 2018
- A Practical Review of C-Peptide Testing in DiabetesDiabetes Therapy, 2017
- A high-throughput mass spectrometry assay to simultaneously measure intact insulin and C-peptideClinica Chimica Acta, 2016
- The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometryJournal of Immunological Methods, 2009
- Assessment of the effects of insulin secretagogues in humansDiabetes, Obesity and Metabolism, 2000